IL-2 targeted to CD8+ T cells promotes robust effector T cell responses and potent antitumor immunity.
Moynihan KD, Kumar MP, Sultan H, Pappas DC, Park T, Chin SM, Bessette P, Lan RY, Nguyen HC, Mathewson ND, Ni I, Chen W, Lee Y, Liao-Chan S, Chen J, Schumacher TNM, Schreiber RD, Yeung YA, Djuretic IM.
Moynihan KD, et al. Among authors: sultan h.
Cancer Discov. 2024 Apr 2. doi: 10.1158/2159-8290.CD-23-1266. Online ahead of print.
Cancer Discov. 2024.
PMID: 38563906